RLAY

Company Overview — What Does Relay Therapeutics, Inc. Do?

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Relay Therapeutics, Inc. (RLAY) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sanjiv K. Patel and employs approximately 330 people. With a market capitalization of $1.9B, RLAY is one of the notable companies in the Healthcare sector.

Relay Therapeutics, Inc. (RLAY) Stock Rating — Hold (April 2026)

As of April 2026, Relay Therapeutics, Inc. receives a Hold rating with a composite score of 35.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.RLAY ranks #1,535 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Relay Therapeutics, Inc. ranks #133 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RLAY Stock Price and 52-Week Range

Relay Therapeutics, Inc. (RLAY) currently trades at $14.95. The stock lost $0.05 (0.3%) in the most recent trading session. The 52-week high for RLAY is $11.49, which means the stock is currently trading 30.1% from its annual peak. The 52-week low is $1.77, putting the stock 742.3% above its annual trough. Recent trading volume was 2.8M shares, reflecting moderate market activity.

Is RLAY Overvalued or Undervalued? — Valuation Analysis

Relay Therapeutics, Inc. (RLAY) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.25x, versus the sector average of 2.75x. The price-to-sales ratio is 288.32x, compared to 1.66x for the average Healthcare stock.

At current multiples, Relay Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Relay Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Relay Therapeutics, Inc. (RLAY) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -54.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -49.8% versus the sector average of -33.1%.

The operating margin is -6228.2% (sector: -66.1%). Net profit margin stands at -5699.4%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RLAY Debt, Balance Sheet, and Financial Health

Relay Therapeutics, Inc. has a debt-to-equity ratio of 10.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 22.61x, indicating strong short-term liquidity. Total debt on the balance sheet is $30M. Cash and equivalents stand at $92M.

RLAY has a beta of 1.65, meaning it is more volatile than the broader market — a $10,000 investment in RLAY would be expected to move 65.5% more than the S&P 500 on any given day. The stability factor score for Relay Therapeutics, Inc. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Relay Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Relay Therapeutics, Inc. reported revenue of $8M and earnings per share (EPS) of $-1.61. Net income for the quarter was $-310M. Operating income came in at $-338M.

In FY 2025, Relay Therapeutics, Inc. reported revenue of $15M and earnings per share (EPS) of $-1.61. Net income for the quarter was $-276M. Revenue grew 53.4% year-over-year compared to FY 2024. Operating income came in at $-303M.

In Q3 2025, Relay Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.43. Net income for the quarter was $-74M. Operating income came in at $-80M.

In Q2 2025, Relay Therapeutics, Inc. reported revenue of $677,000 and earnings per share (EPS) of $-0.41. Net income for the quarter was $-70M. Operating income came in at $-77M.

Over the past 8 quarters, Relay Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $8M. Investors analyzing RLAY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RLAY Dividend Yield and Income Analysis

Relay Therapeutics, Inc. (RLAY) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RLAY Momentum and Technical Analysis Profile

Relay Therapeutics, Inc. (RLAY) has a momentum factor score of 77/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 7/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RLAY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Relay Therapeutics, Inc. (RLAY) ranks #133 out of 838 stocks based on the Blank Capital composite score. This places RLAY in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RLAY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RLAY vs S&P 500 (SPY) comparison to assess how Relay Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

RLAY Next Earnings Date

No upcoming earnings date has been announced for Relay Therapeutics, Inc. (RLAY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RLAY? — Investment Thesis Summary

Relay Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 25/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. Price momentum is positive at 77/100, suggesting the trend favors buyers. High volatility (stability score 28/100) increases portfolio risk.

In summary, Relay Therapeutics, Inc. (RLAY) earns a Hold rating with a composite score of 35.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RLAY stock.

Related Resources for RLAY Investors

Explore more research and tools: RLAY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RLAY head-to-head with peers: RLAY vs AZN, RLAY vs SLGL, RLAY vs VMD.